Clinical trial
Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic…
NCT00006903 · Gynecologic Oncology Group, Other · Unknown status
Key facts
| NCT number | NCT00006903 |
|---|---|
| Title | Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer |
| Official title | Phase II Study of Faslodex ? in Recurrent/Metastatic Endometrial Carcinoma |
| Lead sponsor | Gynecologic Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Uterine Corpus Carcinoma, Stage III Uterine Corpus Cancer AJCC v7, Stage IV Uterine Corpus Cancer AJCC v7 |
| Intervention type | Drug |
| Interventions | Fulvestrant |
| Enrollment | 67 |
| Start date | Aug 30, 2004 |
| Primary completion | Mar 17, 2008 |
| First posted | Jan 27, 2003 |
| Last update posted | Mar 20, 2019 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: